HK Stock Market Move | BIOCYTOGEN-B(02315) rose more than 4% and completed the localization deployment of DeepSeek. The development strategy of antibody drugs "Thousand Mice and Ten Thousand Antigens" has been upgraded.

BiocytoGen-B (02315) rose more than 4% in the afternoon, up 4.49% to HK$8.61 by the time of publication, with a turnover of HK$2.0477 million. On the news front, Baiose congratulated noon announced that it has recently completed the localization deployment of the AI-driven antibody drug research platform DeepSeek and achieved comprehensive synergy with the company's core business "Thousand Mice, Ten Thousand Antibodies" plan. The company launched the "Thousand Mice, Ten Thousand Antibodies" plan in 2020, targeting 1000+ potential antibody drug targets, conducting antibody research on the RenMab, RenLite, RenNano, and other fully human antibody mouse platforms. Currently, it has obtained 500,000+ fully human antibody sequence molecules for 1000+ drug targets, covering various forms of antibody molecules such as monoclonal antibodies, bispecific antibodies, nanobodies, with high affinity, low immunogenicity, and drug-like advantages. In the future, this library of fully human antibody molecules will rapidly increase to tens of millions. Baiose pointed out that through the combination of the "Thousand Mice, Ten Thousand Antibodies" antibody molecule library and the DeepSeek platform, it can provide global pharmaceutical companies with new single, bispecific, and multispecific antibody molecular skeletons. In the future, with the deep integration of the "Thousand Mice, Ten Thousand Antibodies" and DeepSeek, Baiose will provide global pharmaceutical companies with more efficient research and development tools and a more comprehensive library of antibody molecules, promoting the rapid development of antibody drugs.